hcv in 4

HCV-IN-4, a potent and orally active inhibitor of HCV NS5A, demonstrates significant efficacy against genotypes GT1a, GT2b, GT3a, and the GT1a mutations Y93H and L31V. Its half-maximal effective concentrations (EC90s) are 3 pM, 0.3 nM, 0.01 nM, 0.5 nM, and 0.02 nM, respectively[1].

HCV NS4A Protein (18-40) (JT strain) is a peptide derived from residues 18 to 40 of the HCV NS4A protein, enhancing the catalytic efficiency of NS3 protease [1].